FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2053655447> ?p ?o ?g. }

• W2053655447 endingPage "719" @default.
• W2053655447 startingPage "707" @default.
• W2053655447 abstract "Triple therapy with peginterferon/ribavirin (PR) plus an NS3 protease inhibitor has emerged as the standard-of-care for patients with chronic hepatitis C genotype-1. We provide a detailed safety analysis comparing PR to boceprevir plus PR (BOC/PR) across three phase 2/3 studies.SPRINT-1 was an open-label phase 2 study in 595 treatment-naive patients. In the two phase 3 studies, 1500 patients (1097 treatment-naive, SPRINT-2; 403 treatment-failure, RESPOND-2) were randomized to receive PR alone, or one of two regimens where BOC was added to PR after a 4-wk PR lead-in. In this analysis, the respective BOC/PR and PR arms were combined for all three trials. The benefit of shortened duration of treatment using response-guided therapy (RGT) was also explored in the SPRINT-2 trial.Only two adverse events, anaemia and dysgeusia, occurred 20% more often with the BOC-containing regimens compared with PR. Nausea, diarrhoea and neutropenia were the only other common events with an incidence of at least 5% greater when BOC was added to the PR backbone. The proportions of patients reporting serious adverse events (AE), life-threatening AEs, and study drug discontinuation because of an AE were similar in the PR and BOC/PR arms. In treatment-naive patients, RGT generally did not result in a lower frequency of common AEs; however, RGT led to decreased exposure to all 3 study drugs and to a decrease in the mean duration of several clinically relevant AEs such as anaemia, neutropenia, fatigue and depression, as well as earlier normalization of haemoglobin and neutrophil counts.The safety profile of BOC combination therapy largely reflects the known profile of peginterferon and ribavirin, with incremental haematolgical effects and dysgeusia. Shorter treatment duration with RGT significantly reduced the duration of AEs." @default.
• W2053655447 created "2016-06-24" @default.
• W2053655447 creator A5002183557 @default.
• W2053655447 creator A5019214361 @default.
• W2053655447 creator A5019949529 @default.
• W2053655447 creator A5021954687 @default.
• W2053655447 creator A5029165106 @default.
• W2053655447 creator A5037852458 @default.
• W2053655447 creator A5038247507 @default.
• W2053655447 creator A5039066540 @default.
• W2053655447 creator A5042613443 @default.
• W2053655447 creator A5043581009 @default.
• W2053655447 creator A5044983037 @default.
• W2053655447 creator A5054201295 @default.
• W2053655447 creator A5056578595 @default.
• W2053655447 creator A5057909457 @default.
• W2053655447 creator A5068300683 @default.
• W2053655447 creator A5071962316 @default.
• W2053655447 creator A5075978351 @default.
• W2053655447 creator A5076023192 @default.
• W2053655447 creator A5081241458 @default.
• W2053655447 creator A5086628652 @default.
• W2053655447 creator A5087810948 @default.
• W2053655447 creator A5088891566 @default.
• W2053655447 creator A5090499818 @default.
• W2053655447 date "2013-10-09" @default.
• W2053655447 modified "2023-10-18" @default.
• W2053655447 title "Overall safety profile of boceprevir plus peginterferon alfa‐2b and ribavirin in patients with chronic hepatitis C genotype 1: a combined analysis of 3 phase 2/3 clinical trials" @default.
• W2053655447 cites W2027545702 @default.
• W2053655447 cites W2046658390 @default.
• W2053655447 cites W2054043296 @default.
• W2053655447 cites W2064546869 @default.
• W2053655447 cites W2091664007 @default.
• W2053655447 cites W2125963799 @default.
• W2053655447 cites W2127685726 @default.
• W2053655447 cites W2141214317 @default.
• W2053655447 cites W2143559032 @default.
• W2053655447 cites W2149777957 @default.
• W2053655447 cites W2317554121 @default.
• W2053655447 cites W4248237735 @default.
• W2053655447 doi "https://doi.org/10.1111/liv.12300" @default.
• W2053655447 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24118703" @default.
• W2053655447 hasPublicationYear "2013" @default.
• W2053655447 type Work @default.
• W2053655447 sameAs 2053655447 @default.
• W2053655447 citedByCount "16" @default.
• W2053655447 countsByYear W20536554472014 @default.
• W2053655447 countsByYear W20536554472015 @default.
• W2053655447 countsByYear W20536554472016 @default.
• W2053655447 countsByYear W20536554472017 @default.
• W2053655447 countsByYear W20536554472020 @default.
• W2053655447 crossrefType "journal-article" @default.
• W2053655447 hasAuthorship W2053655447A5002183557 @default.
• W2053655447 hasAuthorship W2053655447A5019214361 @default.
• W2053655447 hasAuthorship W2053655447A5019949529 @default.
• W2053655447 hasAuthorship W2053655447A5021954687 @default.
• W2053655447 hasAuthorship W2053655447A5029165106 @default.
• W2053655447 hasAuthorship W2053655447A5037852458 @default.
• W2053655447 hasAuthorship W2053655447A5038247507 @default.
• W2053655447 hasAuthorship W2053655447A5039066540 @default.
• W2053655447 hasAuthorship W2053655447A5042613443 @default.
• W2053655447 hasAuthorship W2053655447A5043581009 @default.
• W2053655447 hasAuthorship W2053655447A5044983037 @default.
• W2053655447 hasAuthorship W2053655447A5054201295 @default.
• W2053655447 hasAuthorship W2053655447A5056578595 @default.
• W2053655447 hasAuthorship W2053655447A5057909457 @default.
• W2053655447 hasAuthorship W2053655447A5068300683 @default.
• W2053655447 hasAuthorship W2053655447A5071962316 @default.
• W2053655447 hasAuthorship W2053655447A5075978351 @default.
• W2053655447 hasAuthorship W2053655447A5076023192 @default.
• W2053655447 hasAuthorship W2053655447A5081241458 @default.
• W2053655447 hasAuthorship W2053655447A5086628652 @default.
• W2053655447 hasAuthorship W2053655447A5087810948 @default.
• W2053655447 hasAuthorship W2053655447A5088891566 @default.
• W2053655447 hasAuthorship W2053655447A5090499818 @default.
• W2053655447 hasBestOaLocation W20536554471 @default.
• W2053655447 hasConcept C126322002 @default.
• W2053655447 hasConcept C197934379 @default.
• W2053655447 hasConcept C203014093 @default.
• W2053655447 hasConcept C2522874641 @default.
• W2053655447 hasConcept C2776408679 @default.
• W2053655447 hasConcept C2776455275 @default.
• W2053655447 hasConcept C2776694085 @default.
• W2053655447 hasConcept C2777054765 @default.
• W2053655447 hasConcept C2777063308 @default.
• W2053655447 hasConcept C2777159539 @default.
• W2053655447 hasConcept C2778159067 @default.
• W2053655447 hasConcept C2778248108 @default.
• W2053655447 hasConcept C2778375690 @default.
• W2053655447 hasConcept C2778715236 @default.
• W2053655447 hasConcept C2780040827 @default.
• W2053655447 hasConcept C71924100 @default.
• W2053655447 hasConcept C90924648 @default.
• W2053655447 hasConceptScore W2053655447C126322002 @default.
• W2053655447 hasConceptScore W2053655447C197934379 @default.
• W2053655447 hasConceptScore W2053655447C203014093 @default.
• W2053655447 hasConceptScore W2053655447C2522874641 @default.
• W2053655447 hasConceptScore W2053655447C2776408679 @default.

• next